{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["22(1)"],"submitter":["Lai MY"],"pubmed_abstract":["<h4>Background</h4>Both Response Evaluation Criteria in Solid Tumors (RECIST) and tumor regression grade (TRG) play key roles in evaluating tumor response. We analyzed the consistency of TRG and RECIST 1.1 for gastric cancer (GC) patients and compared their prognostic values.<h4>Methods</h4>Patients with GC who received preoperative chemotherapy or chemoimmunotherapy and had records of TRG from December 2013 to October 2021 were enrolled retrospectively. TRG 0-1 and 2-3 are considered as corresponding to complete response (CR)/partial response (PR) and stable disease (SD)/progress disease (PD) in RECIST 1.1, respectively. The primary endpoints were disease-free survival (DFS) and overall survival (OS). The consistency of RECIST and TRG was examined by kappa statistics. Survival analysis wa"],"journal":["BMC cancer"],"pagination":["1031"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9526302"],"repository":["biostudies-literature"],"pubmed_title":["Comparison of response evaluation criteria in solid tumors and tumor regression grade in evaluating the effect of preoperative systemic therapy of gastric cancer."],"pmcid":["PMC9526302"],"pubmed_authors":["Kang SY","Qiu MZ","Quan TT","Sun YT","Yang LQ","Li YH","Lai MY","Guan WL","Zhou ZW","Xu RH","Lu SX","He CY","Wang FH","Luo HY"],"additional_accession":[]},"is_claimable":false,"name":"Comparison of response evaluation criteria in solid tumors and tumor regression grade in evaluating the effect of preoperative systemic therapy of gastric cancer.","description":"<h4>Background</h4>Both Response Evaluation Criteria in Solid Tumors (RECIST) and tumor regression grade (TRG) play key roles in evaluating tumor response. We analyzed the consistency of TRG and RECIST 1.1 for gastric cancer (GC) patients and compared their prognostic values.<h4>Methods</h4>Patients with GC who received preoperative chemotherapy or chemoimmunotherapy and had records of TRG from December 2013 to October 2021 were enrolled retrospectively. TRG 0-1 and 2-3 are considered as corresponding to complete response (CR)/partial response (PR) and stable disease (SD)/progress disease (PD) in RECIST 1.1, respectively. The primary endpoints were disease-free survival (DFS) and overall survival (OS). The consistency of RECIST and TRG was examined by kappa statistics. Survival analysis wa","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2025-04-26T12:03:47.64Z","creation":"2025-02-19T00:23:49.174Z"},"accession":"S-EPMC9526302","cross_references":{"pubmed":["36183074"],"doi":["10.1186/s12885-022-10125-1"]}}